Sweden
· Delayed Price · Currency is SEK Quia Pharma AB Statistics
Total Valuation
Quia Pharma AB has a market cap or net worth of SEK 14.14 million. The enterprise value is 15.25 million.
| Market Cap | 14.14M |
| Enterprise Value | 15.25M |
Important Dates
The next estimated earnings date is Thursday, May 22, 2025.
| Earnings Date | May 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Quia Pharma AB has 1.68 billion shares outstanding. The number of shares has increased by 1,173.14% in one year.
| Current Share Class | 1.68B |
| Shares Outstanding | 1.68B |
| Shares Change (YoY) | +1,173.14% |
| Shares Change (QoQ) | +282.23% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 0.32% |
| Float | 1.67B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.74 |
| PB Ratio | 0.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.53 |
| EV / Sales | 33.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.16, with a Debt / Equity ratio of 0.07.
| Current Ratio | 0.16 |
| Quick Ratio | 0.07 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -51.57 |
Financial Efficiency
Return on equity (ROE) is -183.07% and return on invested capital (ROIC) is -32.03%.
| Return on Equity (ROE) | -183.07% |
| Return on Assets (ROA) | -26.40% |
| Return on Invested Capital (ROIC) | -32.03% |
| Return on Capital Employed (ROCE) | -83.56% |
| Revenue Per Employee | 153,333 |
| Profits Per Employee | -9.64M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.29% in the last 52 weeks. The beta is 0.65, so Quia Pharma AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -87.29% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 45.49 |
| Average Volume (20 Days) | 30,942,798 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Quia Pharma AB had revenue of SEK 460,000 and -28.93 million in losses. Loss per share was -0.03.
| Revenue | 460,000 |
| Gross Profit | 332,000 |
| Operating Income | -13.67M |
| Pretax Income | -28.93M |
| Net Income | -28.93M |
| EBITDA | -9.71M |
| EBIT | -13.67M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 2,000 in cash and 1.11 million in debt, giving a net cash position of -1.11 million or -0.00 per share.
| Cash & Cash Equivalents | 2,000 |
| Total Debt | 1.11M |
| Net Cash | -1.11M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 16.35M |
| Book Value Per Share | 0.01 |
| Working Capital | -5.35M |
Cash Flow
| Operating Cash Flow | -10.17M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 72.17% |
| Operating Margin | -2,970.65% |
| Pretax Margin | -6,288.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Quia Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,173.14% |
| Shareholder Yield | -1,173.14% |
| Earnings Yield | -204.60% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on August 1, 2023. It was a reverse split with a ratio of 0.01.
| Last Split Date | Aug 1, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
Quia Pharma AB has an Altman Z-Score of -1.87. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.87 |
| Piotroski F-Score | n/a |